PL3027600T3 - 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn - Google Patents
1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smnInfo
- Publication number
- PL3027600T3 PL3027600T3 PL14750931.9T PL14750931T PL3027600T3 PL 3027600 T3 PL3027600 T3 PL 3027600T3 PL 14750931 T PL14750931 T PL 14750931T PL 3027600 T3 PL3027600 T3 PL 3027600T3
- Authority
- PL
- Poland
- Prior art keywords
- deficiency
- related conditions
- pyridazine derivatives
- disubstituted pyridazine
- smn
- Prior art date
Links
- -1 1,4-disubstituted pyridazine Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860388P | 2013-07-31 | 2013-07-31 | |
| PCT/US2014/048984 WO2015017589A1 (en) | 2013-07-31 | 2014-07-30 | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3027600T3 true PL3027600T3 (pl) | 2022-08-08 |
Family
ID=51352849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14750931.9T PL3027600T3 (pl) | 2013-07-31 | 2014-07-30 | 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20160184305A1 (pl) |
| EP (2) | EP4105208A1 (pl) |
| JP (3) | JP6461150B2 (pl) |
| KR (2) | KR102318727B1 (pl) |
| CN (1) | CN105636953B (pl) |
| AU (1) | AU2014296255B2 (pl) |
| BR (1) | BR112016001899B1 (pl) |
| CA (1) | CA2918805C (pl) |
| EA (1) | EA030631B1 (pl) |
| ES (1) | ES2917979T3 (pl) |
| MX (2) | MX383686B (pl) |
| PL (1) | PL3027600T3 (pl) |
| PT (1) | PT3027600T (pl) |
| WO (1) | WO2015017589A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN105636953B (zh) * | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| EP3298017B1 (en) * | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| US10357543B2 (en) | 2015-11-16 | 2019-07-23 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein |
| CA3119019C (en) * | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| WO2019000144A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种表达aitr基因的cho细胞及其应用 |
| WO2019000150A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种tl6高表达的重组cho细胞的构建方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| CN114174514A (zh) | 2019-07-25 | 2022-03-11 | 诺华股份有限公司 | 可调节的表达系统 |
| TW202131920A (zh) | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| WO2022255553A1 (ko) | 2021-06-03 | 2022-12-08 | 주식회사 엠디헬스케어 | 락토바실러스 파라카세이 유래 세포외소포를 포함하는 안질환 예방 또는 치료용 조성물 |
| JP2024529399A (ja) * | 2021-07-19 | 2024-08-06 | ヌマット テクノロジーズ インコーポレーテッド | 液体組成物中の汚染物質を除去するためのプロセスおよび製品 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2516040C2 (de) * | 1974-06-10 | 1984-12-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE2427943C2 (de) * | 1974-06-10 | 1984-08-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| CA2174838A1 (en) | 1993-11-24 | 1995-06-01 | John Wityak | Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
| HUP0301391A3 (en) * | 2000-02-11 | 2010-03-29 | Vertex Pharma | Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use |
| EP1133993A1 (en) * | 2000-03-10 | 2001-09-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Substances for the treatment of spinal muscular atrophy |
| DE60131160T2 (de) * | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
| US6376508B1 (en) * | 2000-12-13 | 2002-04-23 | Academia Sinica | Treatments for spinal muscular atrophy |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的噁二唑 |
| EP1562945B1 (en) | 2002-11-11 | 2006-11-15 | Neurosearch A/S | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| US7595316B2 (en) | 2003-06-27 | 2009-09-29 | Banyu Pharmaceutical Co., Ltd. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| CA2533889A1 (en) | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US7655657B2 (en) * | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| FR2868780B1 (fr) | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| EP1753740A2 (en) | 2004-05-21 | 2007-02-21 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| EP1765348B1 (en) | 2004-06-18 | 2016-08-03 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| ATE533491T1 (de) | 2004-09-21 | 2011-12-15 | Trobio Ab | Stabilisierte protease zusammensetzungen enthaltend eine serinprotease, morpholin-derivate und reversible serinprotease- inhibitoren |
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
| GB0517184D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| TW200813051A (en) * | 2006-05-08 | 2008-03-16 | Neurogen Corp | Substituted azaspiro derivatives |
| NZ573735A (en) * | 2006-05-19 | 2011-10-28 | Abbott Lab | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| WO2008058064A1 (en) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Amine-linked multicyclic compounds as inhibitors of the proline transporter |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| GB0704394D0 (en) | 2007-03-07 | 2007-04-11 | Senexis Ltd | Compounds |
| GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| EP2231600B1 (en) | 2007-11-16 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| CA2716109C (en) * | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| WO2009137503A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
| US20110142758A1 (en) * | 2008-06-10 | 2011-06-16 | Neurosearch A/S | Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| BRPI0914891A2 (pt) | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| AU2009289649B2 (en) * | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| WO2010037210A1 (en) | 2008-10-03 | 2010-04-08 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| CA2739491A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Azine derivatives and methods of use thereof |
| KR101701367B1 (ko) | 2008-11-04 | 2017-02-02 | 케모센트릭스, 인크. | Ｃｘｃｒ７의 모듈레이터 |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| EP2456438A2 (en) * | 2009-07-23 | 2012-05-30 | Novartis AG | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| MX2012002641A (es) | 2009-09-10 | 2012-03-14 | Hoffmann La Roche | Inhibidores de cinasa janus (jak). |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| EP2501236B1 (en) * | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US20130096160A1 (en) | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2606022A2 (en) * | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| EA201391348A8 (ru) * | 2011-03-18 | 2014-11-28 | Новартис Аг | КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN105636953B (zh) | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
-
2014
- 2014-07-30 CN CN201480054025.8A patent/CN105636953B/zh not_active Expired - Fee Related
- 2014-07-30 CA CA2918805A patent/CA2918805C/en active Active
- 2014-07-30 MX MX2016001400A patent/MX383686B/es unknown
- 2014-07-30 JP JP2016531875A patent/JP6461150B2/ja not_active Expired - Fee Related
- 2014-07-30 EP EP22159905.3A patent/EP4105208A1/en active Pending
- 2014-07-30 EA EA201690287A patent/EA030631B1/ru not_active IP Right Cessation
- 2014-07-30 PL PL14750931.9T patent/PL3027600T3/pl unknown
- 2014-07-30 BR BR112016001899-0A patent/BR112016001899B1/pt not_active IP Right Cessation
- 2014-07-30 EP EP14750931.9A patent/EP3027600B1/en active Active
- 2014-07-30 KR KR1020167004818A patent/KR102318727B1/ko not_active Expired - Fee Related
- 2014-07-30 ES ES14750931T patent/ES2917979T3/es active Active
- 2014-07-30 WO PCT/US2014/048984 patent/WO2015017589A1/en not_active Ceased
- 2014-07-30 MX MX2020011652A patent/MX2020011652A/es unknown
- 2014-07-30 KR KR1020217034080A patent/KR20210130843A/ko not_active Abandoned
- 2014-07-30 US US14/909,052 patent/US20160184305A1/en not_active Abandoned
- 2014-07-30 AU AU2014296255A patent/AU2014296255B2/en not_active Ceased
- 2014-07-30 PT PT147509319T patent/PT3027600T/pt unknown
-
2018
- 2018-12-25 JP JP2018240458A patent/JP6856614B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-28 US US16/259,441 patent/US11672799B2/en active Active
-
2021
- 2021-03-17 JP JP2021043919A patent/JP7208285B2/ja active Active
-
2023
- 2023-05-23 US US18/322,521 patent/US20240009189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3027600A1 (en) | 2016-06-08 |
| CA2918805A1 (en) | 2015-02-05 |
| CN105636953A (zh) | 2016-06-01 |
| EP3027600B1 (en) | 2022-04-06 |
| KR20210130843A (ko) | 2021-11-01 |
| US20190160062A1 (en) | 2019-05-30 |
| EP4105208A1 (en) | 2022-12-21 |
| JP6856614B2 (ja) | 2021-04-07 |
| BR112016001899A2 (pl) | 2017-09-05 |
| MX383686B (es) | 2025-03-14 |
| CN105636953B (zh) | 2018-01-02 |
| JP2016527272A (ja) | 2016-09-08 |
| KR102318727B1 (ko) | 2021-10-28 |
| AU2014296255A1 (en) | 2016-02-18 |
| PT3027600T (pt) | 2022-06-23 |
| MX2016001400A (es) | 2016-05-05 |
| JP2019059783A (ja) | 2019-04-18 |
| KR20160037199A (ko) | 2016-04-05 |
| ES2917979T3 (es) | 2022-07-12 |
| JP6461150B2 (ja) | 2019-01-30 |
| US20160184305A1 (en) | 2016-06-30 |
| CA2918805C (en) | 2023-02-28 |
| JP7208285B2 (ja) | 2023-01-18 |
| JP2021098753A (ja) | 2021-07-01 |
| MX2020011652A (es) | 2022-09-27 |
| EA201690287A1 (ru) | 2016-07-29 |
| AU2014296255B2 (en) | 2017-08-03 |
| EA030631B1 (ru) | 2018-09-28 |
| US11672799B2 (en) | 2023-06-13 |
| BR112016001899B1 (pt) | 2022-03-15 |
| WO2015017589A1 (en) | 2015-02-05 |
| US20240009189A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3027600T (pt) | Derivados de piridazina 1,4-dissubstituídos e a sua utilização para tratamento de condições relacionadas com deficiência em smn | |
| IL278018A (en) | Methods for the treatment or prevention of ophthalmological conditions | |
| IL237067B (en) | Disubstituted pyridazine analogs at the 4,1 positions and methods for treating conditions associated with smn deficiency | |
| RS67779B1 (sr) | Farmaceutska kompozicija, postupci za lečenje i njihova primena | |
| EP2948097A4 (en) | METHODS, SYSTEMS AND DEVICES FOR TREATING HEART ARRHYTHMIES | |
| IL245101A0 (en) | Derivatives of 1,4-cyclohexylamine and processes for their preparation | |
| EP2977655A4 (en) | SLIDING ELEMENT | |
| IL242437B (en) | Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process | |
| IL244214A0 (en) | Thienopiperidine derivative and its use | |
| ZA201600015B (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| SG10201710538XA (en) | Compositions and methods for treating skin | |
| PL3055679T3 (pl) | Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć | |
| EP2981554A4 (en) | Methods and compositions for treating and preventing disease associated with avb8 integrin | |
| SI3004077T1 (sl) | Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on | |
| PT3004076T (pt) | Novos compostos de 3,4-di-hidro-2h-isoquinolina-1-ona e de 2,3-di-hidro-isoindol-1-ona | |
| EP2980096A4 (en) | 2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof | |
| EP2968550A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | |
| GB201311984D0 (en) | Methods and compounds for preventing or treating osteoarthritis |